TD Cowen raised the firm’s price target on MDxHealth (MDXH) to $7 from $5 and keeps a Buy rating on the shares. The firm said 3Q sales were just shy of consensus with margins/EBITDA better. 2026 should see accelerating sales growth as ExoDx integration takes full effect, which combined with OpEx control will enable expanding positive EBITDA, supporting a favorable view on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH:
- MDxHealth price target raised to $7 from $6 at BTIG
- Positive Outlook for MDxHealth: Strategic Moves and Undervalued Growth Potential Reinforce Buy Rating
- Mdxhealth S.A. Reports Strong Q3 Growth and Strategic Acquisition
- Positive Outlook for MDxHealth: Strategic Acquisition and Focus on High-Return Products Drive Growth Potential
- Mdxhealth Reports Strong Q3 Growth and Strategic Acquisition